Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CONSTATRE: Risperdal Consta Trial Of Relapse Prevention And Effectiveness.

Trial Profile

CONSTATRE: Risperdal Consta Trial Of Relapse Prevention And Effectiveness.

Phase of Trial: Phase III

Latest Information Update: 09 Jun 2014

At a glance

  • Drugs Risperidone (Primary) ; Aripiprazole; Quetiapine
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Acronyms CONSTATRE
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 08 Nov 2011 Cost of relapse results presented at the 14th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research.
    • 01 Nov 2010 Primary endpoint results published in Neuropsychopharmacology
    • 14 Jul 2009 Actual patient number changed from 710 to 753 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top